东阿阿胶: 2025年半年度报告

Core Viewpoint - Dong-E-E-Jiao Co., Ltd. reported a revenue increase of 11.02% year-on-year, reaching approximately 3.05 billion yuan, with a net profit of approximately 817.72 million yuan, reflecting a growth of 10.74% compared to the previous year [1][5]. Company Overview and Key Financial Indicators - The company is listed on the Shenzhen Stock Exchange under the stock code 000423, with a total of 643,976,824 shares outstanding [1]. - The profit distribution plan includes a cash dividend of 12.69 yuan per 10 shares (tax included) [1]. - Key financial metrics for the reporting period include: - Revenue: 3,050,717,291.69 yuan, up 11.02% from 2,747,957,878.26 yuan [5]. - Net profit attributable to shareholders: 817,717,365.38 yuan, up 10.74% from 738,419,138.16 yuan [5]. - Basic earnings per share: 1.2698 yuan, up 10.52% from 1.1489 yuan [5]. - Total assets: 12,782,336,803.13 yuan, down 2.33% from 13,087,136,728.33 yuan [5]. Business Operations - The company focuses on traditional Chinese medicine, particularly in the production of Ejiao (donkey-hide gelatin), which has a history of nearly 3,000 years and is recognized for its health benefits [4]. - Major products include: - Ejiao and its series, accounting for 93.24% of total revenue [8]. - Compound Ejiao syrup, which has been included in treatment guidelines for anemia related to tumors [4]. - New product lines such as "Zhuangben" and "Yanzhenqing" targeting specific health needs [4]. Competitive Advantages - The company emphasizes quality control and innovation, maintaining a 100% pass rate for product inspections and certifications [4]. - It has established a strong brand presence as a leader in the health supplement market, recognized for its commitment to quality and traditional practices [4]. - The company is actively involved in research and development, collaborating with top academic institutions to enhance product offerings and address market demands [4][6]. Financial Performance Analysis - The company experienced a significant increase in cash flow from investment activities, with a net inflow of approximately 1.11 billion yuan, a 473.91% increase year-on-year [5]. - The cash and cash equivalents rose by 32.18% to approximately 6.63 billion yuan, primarily due to the recovery of matured financial products [5][11]. - Accounts receivable increased by 133.31% to approximately 184.78 million yuan, reflecting the expansion of business operations and new product launches [5][10]. Market and Regional Performance - Revenue from the pharmaceutical industry segment was approximately 2.99 billion yuan, representing 97.88% of total revenue, with a year-on-year growth of 11.28% [8]. - The company saw varied performance across regions, with East China contributing significantly to revenue growth [8].